123 related articles for article (PubMed ID: 29432024)
21. MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer.
Wang L; Wang Z; Huang L; Wu C; Zhang B
Anticancer Drugs; 2019 Mar; 30(3):281-288. PubMed ID: 30601190
[TBL] [Abstract][Full Text] [Related]
22. Biofabrication of nano copper oxide and its aptamer bioconjugate for delivery of mRNA 29b to lung cancer cells.
Wu D; Wang W; He X; Jiang M; Lai C; Hu X; Xi J; Wang M
Mater Sci Eng C Mater Biol Appl; 2019 Apr; 97():827-832. PubMed ID: 30678973
[TBL] [Abstract][Full Text] [Related]
23. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
24. Regression of murine lung tumors by the let-7 microRNA.
Trang P; Medina PP; Wiggins JF; Ruffino L; Kelnar K; Omotola M; Homer R; Brown D; Bader AG; Weidhaas JB; Slack FJ
Oncogene; 2010 Mar; 29(11):1580-7. PubMed ID: 19966857
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/β-catenin Signaling.
Liu T; Wu X; Chen T; Luo Z; Hu X
Clin Cancer Res; 2018 Apr; 24(7):1748-1760. PubMed ID: 28972040
[No Abstract] [Full Text] [Related]
26. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN.
Wang H; Guan X; Tu Y; Zheng S; Long J; Li S; Qi C; Xie X; Zhang H; Zhang Y
J Exp Clin Cancer Res; 2015 Jun; 34(1):59. PubMed ID: 26063204
[TBL] [Abstract][Full Text] [Related]
27. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
[TBL] [Abstract][Full Text] [Related]
28. Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.
Dai B; Hu Y; Duan J; Yang XD
Oncotarget; 2016 Jun; 7(25):38257-38269. PubMed ID: 27203221
[TBL] [Abstract][Full Text] [Related]
29. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional silver nanocluster-hybrid oligonucleotide vehicle for cell imaging and microRNA-targeted gene silencing.
Chen HY; Albert K; Wen CC; Hsieh PY; Chen SY; Huang NC; Lo SC; Chen JK; Hsu HY
Colloids Surf B Biointerfaces; 2017 Apr; 152():423-431. PubMed ID: 28171795
[TBL] [Abstract][Full Text] [Related]
31. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
33. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
[TBL] [Abstract][Full Text] [Related]
34. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
[TBL] [Abstract][Full Text] [Related]
35. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
[TBL] [Abstract][Full Text] [Related]
36. miR-219a-5p enhances the radiosensitivity of non-small cell lung cancer cells through targeting CD164.
Wei T; Cheng S; Fu XN; Feng LJ
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32364222
[TBL] [Abstract][Full Text] [Related]
37. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
38. MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery.
Sayari E; Dinarvand M; Amini M; Azhdarzadeh M; Mollarazi E; Ghasemi Z; Atyabi F
Int J Pharm; 2014 Oct; 473(1-2):304-15. PubMed ID: 24905777
[TBL] [Abstract][Full Text] [Related]
39. Anti prostate cancer therapy: Aptamer-functionalized, curcumin and cabazitaxel co-delivered, tumor targeted lipid-polymer hybrid nanoparticles.
Chen Y; Deng Y; Zhu C; Xiang C
Biomed Pharmacother; 2020 Jul; 127():110181. PubMed ID: 32416561
[TBL] [Abstract][Full Text] [Related]
40. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
